Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Coreceptor therapy has distinct short- and long-term tolerogenic effects intrinsic to autoreactive effector T cells
Matthew Clark, Charles J. Kroger, Qi Ke, Rui Zhang, Karen Statum, J. Justin Milner, Aaron Martin, Bo Wang, Roland Tisch
Matthew Clark, Charles J. Kroger, Qi Ke, Rui Zhang, Karen Statum, J. Justin Milner, Aaron Martin, Bo Wang, Roland Tisch
View: Text | PDF
Research Article Immunology

Coreceptor therapy has distinct short- and long-term tolerogenic effects intrinsic to autoreactive effector T cells

  • Text
  • PDF
Abstract

Immunotherapies are needed in the clinic that effectively suppress β cell autoimmunity and reestablish long-term self-tolerance in type 1 diabetes. We previously demonstrated that nondepleting anti-CD4 (αCD4) and αCD8α antibodies establish rapid and indefinite remission in recent-onset diabetic NOD mice. Diabetes reversal by coreceptor therapy (CoRT) is induced by suppression of pathogenic effector T cells (Teffs) and the selective egress of T cells from the pancreatic lymph nodes and islets that remain free of infiltration in the long term. Here, we defined CoRT-induced events regulating early Teff function and pancreatic residency, and long-term tolerance. TCR-driven gene expression controlling autoreactive Teff expansion and proinflammatory activity was suppressed by CoRT, and islet T cell egress was dependent on sphingosine-1 phosphate. In both murine and human T cells, CoRT upregulated the Foxo1 transcriptional axis, which in turn was required for suppression and efficient pancreatic egress of Teffs. Interestingly, long-term tolerance induced in late-preclinical NOD mice was marked by reseeding of the pancreas by a reduced CD8+ Teff pool exhibiting an exhausted phenotype. Notably, PD-1 blockade, which rescues exhausted Teffs, resulted in diabetes onset in protected animals. These findings demonstrate that CoRT has distinct intrinsic effects on Teffs that impact events early in induction and later in maintenance of self-tolerance.

Authors

Matthew Clark, Charles J. Kroger, Qi Ke, Rui Zhang, Karen Statum, J. Justin Milner, Aaron Martin, Bo Wang, Roland Tisch

×

Figure 10

ND αCD4/αCD8 treatment promotes CD8+ Teff exhaustion.

Options: View larger image (or click on image) Download as PowerPoint
ND αCD4/αCD8 treatment promotes CD8+ Teff exhaustion.
(A–E) Twelve-week-...
(A–E) Twelve-week-old NOD female mice were treated with 2 injections 1 day apart with ND αCD4/αCD8α or control Ab. (A) Insulitis scored by immunohistochemistry 60 days after ND αCD4/αCD8α (n = 10) and control Ab (n = 10). (B) Pancreatic CD4+ and CD8+ T cell numbers were determined via FACS 60 days after treatment with ND αCD4/αCD8α (n = 16) or control Ab (n = 16). (C) Pancreatic and splenic CD44+ CD8+ Teffs were examined by FACS for PD-1 and LAG-3 expression 60 days after treatment with ND αCD4/αCD8α (n = 8) or control Ab (n = 8). (D) Twelve-week-old NOD female mice were treated with ND αCD4/αCD8α (n = 15) and control Ab (n = 14) alone, or 60 days later also received αPD-1 Ab (CoRT plus αPD-1 [n = 16]; isotype control Ab plus αPD-1 Ab [n = 14]), and diabetes onset was monitored. *P < 0.05, **P < 0.01, ***P < 0.001, determined by Student’s t test (A–D) or Kaplan-Meier (E). Error bars depict SD. Data are pooled from 2 or more experiments.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts